All In Biotech

NDA 209805 · Msd Sub Merck

Steglujan

Ertugliflozin, Sitagliptin Phosphate · Oral

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Dec 19, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

43

14 Phase 3, 5 recruiting

FAERS reports

120

75 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 3, 2026.

STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] . STEGLUJAN is a combination of ertugliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, and sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 ) Has not been studied in patients with a history of pancreatitis. ( 1 , 5.2 )

Mechanism: STEGLUJAN STEGLUJAN combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: ertugliflozin, a SGLT2 inhibitor, and sitagliptin, a DPP-4 inhibitor. Ertugliflozin SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Ertugliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, ertugliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • STEGLUJAN · ERTUGLIFLOZIN 15MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET, ORAL · Prescription
  • STEGLUJAN · ERTUGLIFLOZIN 5MG; SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ertugliflozin" as an intervention, any sponsor and status, largest first.

All 43 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea16
  • bradycardia15
  • vomiting15
  • covid-1913
  • covid-19 pneumonia12
  • gastrointestinal haemorrhage12
  • blood glucose increased10
  • cardiac failure9
  • product dose omission issue9
  • hypertension6
  • no adverse event6
  • ketoacidosis5

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20186
201928
202030
202113
20224
202320
202414
20252
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Steglujan (Ertugliflozin/Sitagliptin Phos)

2024 spending

$978K

Beneficiaries

271

1,119 claims

Per beneficiary

$3,607

$17.48 per unit

View as table
YearSpending
2020$993,723
2021$1,469,280
2022$1,532,498
2023$1,376,725
2024$977,514

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.